Category Archives: Prostate Cell

Prostate Cell News is an online publication and email newsletter summarizing the latest prostate cell research.
Subscribe
Published every week since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.

Inhibition of EZH2 Transactivation Function Sensitizes Solid Tumors to Genotoxic Stress

Investigators showed that EZH2 inhibitors could block the transactivation activity of EZH2 and inhibit the growth of CRPC cells, which revealed a previously unappreciated mechanism of action of EZH2 inhibitors and provided a mechanistic basis for potential combination cancer therapies.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Prostate Cancer Cell Proliferation Is Influenced by LDL-Cholesterol Availability and Cholesteryl Ester Turnover

As cholesterol is a key substrate for de novo steroidogenesis in prostate cells, researchers hypothesized that castrate-resistant/advanced prostate cancer cell growth was influenced by the availability of extracellular, low-density lipoprotein (LDL)-derived, cholesterol, which was coupled to intracellular cholesteryl ester homeostasis.
[Cancer & Metabolism]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Prostate Cancer Immunotherapy

The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.
[Expert Opinion On Biological Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

ETS Factors in Prostate Cancer

Scientists summarize the data on the discovery, modeling, molecular taxonomy, lineage plasticity and therapeutic targeting of ETS family members in prostate cancer.
[Cancer Letters]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker

23andMe Holding Co. received FDA clearance for a genetic health risk report on a hereditary prostate cancer marker.
[23andMe Holding Co.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Single-Cell Analysis of Human Primary Prostate Cancer Reveals the Heterogeneity of Tumor-Associated Epithelial Cell States

Researchers uncovered heterogeneous cellular states in prostate epithelial cells marked by high androgen signaling states that were enriched in prostate cancer and identified a population of tumor-associated club cells that may be associated with prostate carcinogenesis.
[Nature Communications]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Overcoming Resistance to Immune Checkpoint Therapy in PTEN-Null Prostate Cancer by Intermittent Anti-PI3Kα/β/δ Treatment

Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.
[Nature Communications]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells

The authors demonstrated that MUC1-C drove global changes in chromatin architecture in the dedifferentiation of CRPC and triple-negative breast cancer cells.
[Molecular Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share

Targeting Protein Arginine Methyltransferase 5 (PRMT5) Suppresses Radiation-Induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation

Scientists performed transcriptomic analysis and confirmed that fractionated ionizing radiation (FIR)-induced neuroendocrine (NE)-like cells share some features of clinical NE prostate cancer, suggesting that FIR-induced NE differentiation represents a clinically-relevant model.
[Molecular Cancer therapeutics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Combined Effect of Heat Shock Protein Inhibitor Geldanamycin and Free Radicals on Photodynamic Therapy of Prostate Cancer

The authors found that the inhibition of Hsp90 could inhibit the overexpression of its client proteins such as anti-apoptotic proteins and androgen receptor, thereby improving the efficacy of photodynamic therapy and inducing prostate cancer cell apoptosis.
[Journal of Materials Chemistry B]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Acquired Resistance to Irradiation or Docetaxel Is Not Associated with Cross-Resistance to Cisplatin in Prostate Cancer Cell Lines

Researchers investigated whether acquired resistance against ionizing radiation or docetaxel chemotherapy—two commonly applied treatment modalities in prostate cancer—influences the cisplatin tolerance in metastatic CRPC cell line models.
[Journal of Cancer Research and Clinical Oncology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share